header logo image


Page 30«..1020..29303132..4050..»

Archive for the ‘Biotechnology’ Category

Cuban Biotechnology develops 15 projects to face the pandemic – Tehran Times

Sunday, April 19th, 2020

Cuban scientists are working on 15 biotechnological projects to deal with COVID-19 that encompass diagnosis and treatment, officials from the BioCubaFarma entity announced.

Orlando Prez Rodrguez, director of Science and Innovation at BioCubaFarma, said that all clinical research and interventions have been duly authorized by Cuban regulatory entities and will be timely evaluated and reported to publicize Cuba's experience in this field.

He explained that 6 of the 15 projects are focused on treatment, the same number is prophylactic, two are diagnosticians and a medical team.

He added that the products focus on increasing people's innate immunity, reducing the viral load at the beginning of the disease and reducing the hyperinflammatory reaction in patients who develop it, especially in vulnerable groups (older adults or those with pathologies of antecedent).

As a sample of the responsiveness of Cuban Biotechnology, 9 of these projects are already in the phase of intervention trials or clinical studies and six are still in the research and development phase in laboratories, in addition to others in the design or early research.

He pointed out that in the treatment, in the initial stage Interferon Alpha 2B is used, for the management of the inflammatory reaction produced by COVID-19, the monoclonal antibody of the Immunoassay Center and a peptide from the Center for Genetic and Biotechnological Engineering are studied (CIGB).

Most products focus on the use of prophylactics, including nasal administration of interferon Alfa (to stimulate immunity), biomodulin-T (for those over 60 years of age), transfer factor (stimulates immunity in vulnerable groups), CIGB 2020 (immuno enhancer) and a vaccine candidate from the Finlay Institute (contains components of the Cuban meningitis vaccine).

Read this article:
Cuban Biotechnology develops 15 projects to face the pandemic - Tehran Times

Read More...

Role of Cuban science and biotechnology against coronavirus addressed – OnCubaNews

Sunday, April 19th, 2020

The president of BioCubaFarma, Eduardo Martnez, highlighted in the Mesa Redonda television program that in the fight against the coronavirus, his institution has a plan that covers different aspects, one of which is to guarantee the medicines designed for the protocols. He ensured their availability for patients who could be diagnosed, even in the worst case scenario.

He said that BioCubaFarma has also joined the production of soaps, disinfectants, hydroalcoholic solutions and protection means. He added that the antiviral action of interferon has been shown to be effective in treating the disease, along with other products developed by the biopharmaceutical industry. He said that many countries had asked Cuba for support in the supply of medicines. To date, 62 nations have requested interferon.

He insisted that asymptomatic patients constitute the fundamental cause of the spread of the epidemic; hence the importance of mass screening to identify suspects and isolate them. It is an international and local challenge, he said. This April 12, more than 2,000 tests were made in Cuba to diagnose the disease.

For his part, the director of the Finlay Vaccine Institute, Dr. Vicente Vrez, reported that even though the search for a vaccine will take time, there are other options to improve patients immune systems.

Cuba, he said, today has two vaccines used to fight both cancer and allergies, and they will start being applied to risk groups. Their purpose is aimed at strengthening peoples immune system. He explained that several researchers are working on a project aimed at finding out the incidence of these vaccines in patients to prevent them from developing a serious condition.

However, he said that the most important thing was social isolation, the use of the facemask and eyeglasses. All this makes it possible to put up a barrier against the virus and decrease the viral load in case of illness.

The director of the Center for Genetic Engineering and Biotechnology, Dr. Mara del Carmen Domnguez Orta, said that the institution has a research base of 20 years. A specific product, Molecule 258, is intended to regulate peoples immune systems and control inflammation of the organs without generating immunosuppression.

It has been applied, she said, in three critically ill patients at the IPK and the Naval Hospital with positive results, but, she pointed out, it is only used when there are no other options and with the prior consent of family members.

She stressed that this medicine is not a cure, but a therapeutic alternative, hence the importance of complying with prevention measures.

Lastly, Dr. Gerardo Guilln Nieto, director of Biomedical Research at the Center for Genetic Engineering and Biotechnology, said that the vaccine to strengthen innate immunity to COVID-19 is in the final phase of study.

The vaccine, which is applied sublingually, enhances immunity to the entry of the virus, he said, explaining that the samples analyzed after the application of the drug confirm that it stimulates the molecules that mark the activation of the innate immune system.

That vaccine will be favorable to the most vulnerable groups and will help them stimulate the immune response against the virus.

Here is the original post:
Role of Cuban science and biotechnology against coronavirus addressed - OnCubaNews

Read More...

Unified website for biotechnology regulation recently launched – Daily Herald

Sunday, April 19th, 2020

WASHINGTON, D.C. In recognition of National Biotechnology Month, the U.S. Department of Agriculture (USDA), the Food and Drug Administration (FDA) and the Environmental Protection Agency (EPA) recently launched a unified website for biotechnology regulation.

The website streamlines information about the three regulatory agencies charged with overseeing agriculture biotechnology products and is part President Donald J. Trumps Executive Order on Modernizing the Regulatory Framework for Agricultural Biotechnology Products.

Agricultural biotechnology has been and will continue to be an essential tool in helping Americas farmers and ranchers feed, fuel and clothe the world, said U.S. Secretary of Agriculture Sonny Perdue.

From producers to consumers, all Americans deserve a government that delivers science-based, common-sense regulations that foster innovation, conserve resources, and protect public healthespecially when it comes to the food supply, said Perdue.

The launch of this unified biotechnology regulation website is proof of President Trumps commitment to provide the American people with sensible regulations in a clear and transparent manner.

EPA is pleased to be working with our partners at USDA, FDA, and across the federal government to implement President Trumps Executive Order and launch this new, coordinated website, said EPA Administrator Wheeler.

This new website will help provide regulatory certainty and clarity to our nations farmers and producers by bringing together information on the full suite of actions the Trump Administration is taking to safely reduce unnecessary regulations and breakdown barriers for these biotechnology products in the marketplace, Wheeler said.

This is a time of unprecedented scientific innovation. Agricultural biotechnology promises to bring dynamic new products to the marketplace, said FDA Commissioner Stephen Hahn, M.D.

At the FDA, we are committed to fostering flexible, risk-based approaches in this field while upholding our mission of protecting and promoting both human and animal health and animal well-being, Hahn said.

For example, by reducing their susceptibility to diseases like novel influenzas and resistance to zoonotic or foreign animal diseases. Our approach balances our internationally respected, science-based review standards, Hahn said, with our ongoing risk-based regulatory approaches to ensure the safety of our food supply.

Background

The Unified Website for Biotechnology Regulation describes the federal review process for certain biotechnology products and allows users to submit questions to the three agencies.

The goals of this website are to provide enhanced customer service to innovators and developers, while ensuring Americans continue to enjoy the safest and most affordable food supply in the world and can learn more about the safe use of biotechnology innovations.

For more information, visit https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/home/.

Read more:
Unified website for biotechnology regulation recently launched - Daily Herald

Read More...

Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors – BioSpace

Sunday, April 19th, 2020

IRVINE, Calif., April 17, 2020 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuros Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc. (PTC), is a veteran biotechnology company executive with extensive experience in drug discovery and development, and a board-certified surgeon. He succeeds Marcio Souza, who joined ClearPoint Neuros Board as PTCs representative in connection with PTCs May 2019 equity investment in ClearPoint Neuro. Mr. Souza, who resigned from his position as PTCs Chief Operating Officer, as was announced by PTC on March 16, 2020, will remain on ClearPoint Neuros Board as an independent member.

Prior to joining PTC, Dr. Klein served in several executive positions with BioElectron Technology Corporation (BioElectron), most recently as BioElectrons Chief Executive Officer and a Director prior to its acquisition by PTC in 2019. Dr. Klein has a BA from the University of Pennsylvania, an MD from Yale University School of Medicine and an MS in epidemiology from the University of Washington School of Public Health.

We are thrilled by the addition of Matt to our board and the contributions he will make to our company and culture, commented Joe Burnett, President and CEO. As a patient-centric company, adding an established physician, scientist and leader to our board will improve our ability to evaluate new technologies and partnerships.

I am very excited to be joining ClearPoint Neuros Board and look forward to bringing my experience as a drug developer and a surgeon to help the company continue its growth and to fulfill its incredibly important mission, said Dr. Klein.

About ClearPoint Neuro

ClearPoint Neuros mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Companys current product portfolio include deep-brain stimulation, laser ablation, biopsy, neuro-aspiration, and delivery of drugs, biologics and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in 60 active clinical sites in the United States. The Companys SmartFlow cannula is being used in partnership or evaluation with more than 20 individual biologics and drug delivery companies in various stages from preclinical research to late stage regulatory trials. To date, more than 3,500 cases have been performed and supported by the Companys field-based clinical specialist team which offers support and services for our partners. For more information, please visit http://www.clearpointneuro.com.

Forward-Looking Statements

Statements herein concerning the Companys plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: future revenues from sales of the Companys ClearPoint Neuro Navigation System products; the Companys ability to market, commercialize and achieve broader market acceptance for the Companys ClearPoint Neuro Navigation System products; and estimates regarding the sufficiency of the Companys cash resources. More detailed information on these and additional factors that could affect the Companys actual results are described in the Risk Factors section of the Companys Annual Report on Form 10-K for the year ended December 31, 2019, which has been filed with the Securities and Exchange Commission.

Contact:Harold A. Hurwitz, Chief Financial Officer(949) 900-6833hhurwitz@clearpointneuro.com

Jacqueline KellerVice President, Marketing(949) 900-6833jkeller@clearpointneuro.com

Here is the original post:
Biotechnology Leader and Surgeon Dr. Matthew Klein Joins ClearPoint Neuro Board of Directors - BioSpace

Read More...

Is bluebird bio Inc (BLUE) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Sunday, April 19th, 2020

The 38 rating InvestorsObserver gives to bluebird bio Inc (BLUE) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 19 percent of stocks in the Biotechnology industry, BLUEs 38 overall rating means the stock scores better than 38 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

bluebird bio Inc (BLUE) stock is trading at $55.58 as of 1:27 PM on Friday, Apr 17, a gain of $3.02, or 5.75% from the previous closing price of $52.56. The stock has traded between $53.64 and $56.80 so far today. Volume today is high. So far 1,578,260 shares have traded compared to average volume of 1,164,930 shares.

To see the top 5 stocks in Biotechnology click here.

Go here to read the rest:
Is bluebird bio Inc (BLUE) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology – Genetic Literacy Project

Sunday, April 19th, 2020

Theres a profound disconnect between what the latest gene-editing methods can do to increase yields and enhance crop disease and stress resistance and the trickle of such improved crops actually getting out into farmers fields.

The first generation of genetically modified (GM) crops has been remarkably successful. The whole world eats food containing ingredients derived from GM crops and feeds them to its myriad agricultural animals and pets. Despite many dire predictions of long-term negative health effects, a quarter century has passed and none have materialized.1 This remarkably clean track record should have assuaged public fears and assured the rapid development and adoption of GM crops of all kinds.

But it hasnt.

Decades after four major commodity biotech crops corn, soybeans, cotton and canola were introduced and rapidly soared to near market saturation in the countries that permitted their cultivation, the number of new GM crops being released to farmers remains tiny.

[Editors note: This article is part one of a four-part series on the progress of agricultural biotechnology. Read part two, part three and part four.]

Yet the need for higher yielding, disease-resistant and stress-tolerant crops grows with each passing year. The pressures of population growth and climate warming are already outpacing the speed with which conventional breeding practices are expanding the global food supply.2 Land and water availability are rapidly becoming limiting, hence the focus is sharply on the intensification of agriculture.3 But the breeding methods that fueled the spectacular advances in agricultural productivity over the 20th century are near exhaustion.

Over the same period, knowledge of plant physiology and genetics has grown at an explosive pace, as has the technology for identifying and modifying genes of agronomic interest. We know vastly more about what genes do and how plant genomes change both naturally and under human intervention than we did even when the first GM crops were introduced in 1996.4

The recent invention and rapid development of gene- or genome-editing technology (aka SSN or sequence-specific nuclease technology) has facilitated a quantum leap in the ease and precision of genetic intervention, positioning researchers to accelerate the increase in crop yields and to make crop plants more resilient to the biotic and abiotic stresses exacerbated by climate warming.5

Yet just a few of the crops that need to be improved are being improved using the latest techniques and of those, only a few reach farmers each year. To understand this deep disconnect between what can be done to improve crops using modern molecular techniques and what is being done requires a look at the tangle of issues around GM technology at the interface between science, business and society.

In this four-part series, I first examine the factors that led to the disconnect between what can be done and what is being done. I then review both the successes and failures of the first generation of GM crops modified using recombinant DNA (rDNA) technology. I next introduce the new gene-editing technologies and what they promise. And finally, I take a look at the regulatory, political and business decisions that actually determine what gets out of research laboratories and into farmers fields. The entire essay is available as a single publication from the author. Please email [emailprotected].

Part 1: The origins of the disconnect between the science and the farmer

Public resistance to innovation is not unusual, but hardly universal. People line up for the newest Apple iPhone, but have to be persuaded to try a GM apple that doesnt turn brown. Resistance generally subsides as a technology is widely adopted and proves harmless. GM technology in medicine, for example, is now broadly accepted, be it human insulin or any of the many new protein-based therapeutics. But the controversies around GM crops have persisted, and indeed intensified through the deliberate vilification efforts of both individuals and organizations.6,7

According to polls, the public remains largely ignorant of what GM organisms (GMOs) are and of how modern molecular methods fit into the long history of crop improvement.8 Because fear-based disinformation strategies are so effective, what has grown instead is the widespread conviction that GMOs are bad, meaning variously that they are harmful to health, unnatural, or produced by big biotech companies that unfairly exploit farmers.7,9

Part of the problem is that public awareness of genetic modification in agriculture is recent, arguably dating back only to the late 1980s when controversies erupted over field testing of the so-called ice-minus bacterium modified to eliminate a protein that promotes ice formation on the leaves of strawberries.10 Yet in a strictly scientific context, genetic modification denotes the entire spectrum of human interventions in the genetics of other organisms over more than 10 millenia.11

For crop plants, these encompass domestication, breeding, mutation breeding and, most recently, genetic improvement by molecular techniques. All involve genetic changes, aka mutations. Domestication and conventional plant breeding rely on organisms inherent genetic variation.

Direct genetic manipulation of crop plants using chemical and radiation mutagenesis (mutation breeding) dates back to the 1930s.12 But even now, few people other than plant breeders are aware that crops have long been improved through deliberate efforts to induce new mutations using both chemicals and irradiation. So today, it is the general understanding that genetically modified organisms (GMOs) are only those that have been modified by molecular methods. That is, most people think genetic modification is quite new.

And then theres what the regulators built

As if this were not sufficiently problematic, the way in which the regulatory environment evolved reinforced suspicions about GM safety. Early efforts to regulate the commercial introduction of GM crops emphasized the need to regulate new crop traits rather than the particular method by which they were introduced. But thats not what happened.

Starting from the beginning of the regulatory activities in the late 1980s, the U.S. agencies that oversee GM organisms have regulated only organisms modified by molecular methods and theyve regulated all of them, without regard to either nature of the organism or the trait that was added.13 This has been true of the US Department of Agriculture (USDA) and the Environmental Protection Agency (EPA), although the Food and Drug Administration has generally followed its practice of post-market oversight. None of the agencies subjected new crop varieties produced by the older methods of chemical and radiation mutagenesis to regulatory oversight.

Complying with the regulatory requirements proved not only time consuming and prohibitively expensive to developers,14 but also reinforced the altogether unfounded popular conviction that molecular methodology is dangerous. Both negative popular views of GM foods and the high regulatory costs associated with their introduction have shaped the present availability of GMOs in agriculture. Indeed, it is virtually impossible to understand the contemporary paucity of GM crop varieties without considering both regulatory and acceptance issues.

The recent development of gene-editing methods has led to a new round of public and bureaucratic controversy worldwide over what should be classified as a GMO and subject to regulatory oversight. Because gene-editing techniques15 introduce the same kinds of mutations as the older mutagenesis methods, crops modified by gene editing can be indistinguishable at the molecular level from those improved by mutation breeding.

Mutation breeding has been in safe use for a century, hence there is no scientifically defensible rationale for imposing regulations on crops with the same kinds of genetic changes produced by the new, far more precise methods. This is being recognized in some countries by decreasing the regulatory burden on certain types of crop modifications produced by gene-editing techniques.

However, in 2018 the European Court of Justice ruled that gene-edited crops should undergo the same level of regulatory scrutiny as crops modified by older molecular methods.16 As they have over the past 4 decades, the outcome of such regulatory decisions will profoundly influence the kinds of genetic improvements that will be undertaken and actually become available to farmers and consumers.

Thus both public opinion and regulatory practices have made major contributions to the disconnect between the modern science of crop improvement and the farmer.

1EC (2010). A decade of EUfunded GMO research (20012010). European Commission https://ec.europa.eu/research/biosociety/pdf/a_decade_of_eu-funded_gmo_research.pdf; NASEM (2016). Genetically Engineered Crops: Experiences and Prospects. National Academies of Sciences, Engineering, and Medicine 978-0-309-43735-6 http://www.nap.edu/catalog/23395/genetically-engineered-crops-experiences-and-prospects

2Ray DK et al. (2013). Yield trends are insufficient to double global crop production by 2050. PloS One 8:e66428.

3Tilman D et al. (2011). Global food demand and the sustainable intensification of agriculture. Proc Natl Acad Sci USA 108:20260-4.

4Richroch AE (2013). Assessment of GE food safety using -omics techniques and long-term animal feeding studies. New Biotechnol 30:351-54; Fedoroff NV (2013). Plant transposons and genome dynamics in evolution. (Wiley-Blackwell, Oxford, UK), p.212; Anderson JE et al. (2016). Genomic variation and DNA repair associated with soybean transgenesis: a comparison to cultivars and mutagenized plants. BMC Biotechnol 16:41.

5Podevin N et al. (2013). Site-directed nucleases: a paradigm shift in predictable, knowledge-based plant breeding. Trends Biotechnol 31:375-83; Zhang D et al. (2016). Targeted gene manipulation in plants using the CRISPR/Cas technology. J Genet Genomics 43:251-62; Zhang Y et al. (2019). The emerging and uncultivated potential of CRISPR technology in plant science. Nature Plants 5:778-94.

6Apel A (2010). The costly benefits of opposing agricultural biotechnology. New Biotechnol 27:635-40.

7Ryan CD et al. (2019). Monetizing disinformation in the attention economy: The case of genetically modified organisms (GMOs). European Management J 38:7-18.

8Funk C et al. (2015). Public and scientists views on science and society. Pew Research Center http://www.pewinternet.org/2015/01/29/public-and-scientists-views-on-science-and-society/

9Funk C and Kennedy B (2016). Public opinion about genetically modified foods and trust in scientists connected with these foods. Pew Research Center http://www.pewinternet.org/2016/12/01/public-opinion-about-genetically-modified-foods-and-trust-in-scientists-connected-with-these-foods/

10Palca J (1986). Ice-minus bacteria: Further snag and further delay. Nature 320:2.

11Fedoroff NV (2015). Food in a future of 10 billion. Agricult Food Security 4:11.

12Ahloowalia B et al. (2004). Global impact of mutation-derived varieties. Euphytica 135:187-204.

13Fedoroff NV (2013). Will common sense prevail? Trends Genet 29:188-9; Wolt JD et al. (2016). The regulatory status of genomeedited crops. Plant Biotechnol J 14:510-8; Van Eenennaam A and Fedoroff N. How the federal government can get biotech regulation right. Des Moines Register, 1 March 2018

14McDougall P (2011). The cost and time involved in the discovery, development and authorisation of a new plant biotechnology derived trait. Crop Life International https://croplife.org/plant-biotechnology/regulatory-2/cost-of-bringing-a-biotech-crop-to-market/

15Kleter GA et al. (2019). Gene-edited crops: towards a harmonized safety assessment. Trends Biotechnol 37:443-7.

16Kupferschmidt K (2018). EU verdict on CRISPR crops dismays scientists. Science 361:435.

Nina V. Fedoroff is an Emeritus Evan Pugh Professor atPenn State University

The rest is here:
Viewpoint: How consumer fear and misguided regulation limit the progress of crop biotechnology - Genetic Literacy Project

Read More...

Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? – InvestorsObserver

Sunday, April 19th, 2020

The 72 rating InvestorsObserver gives to Iovance Biotherapeutics Inc (IOVA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 84 percent of stocks in the Biotechnology industry, IOVAs 72 overall rating means the stock scores better than 72 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 72 means the stock is more attractive than 72 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock has risen 13.99% while the S&P 500 is unchanged 0% as of 9:50 AM on Tuesday, Apr 14. IOVA is higher by $4.23 from the previous closing price of $30.23 on volume of 285,317 shares. Over the past year the S&P 500 is down -4.95% while IOVA is higher by 209.06%. IOVA lost -$1.59 per share the over the last 12 months.

To screen for more stocks like IOVA click here.

Excerpt from:
Biotechnology Industry: Does Iovance Biotherapeutics Inc (IOVA) Stock Beat its Rivals? - InvestorsObserver

Read More...

Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Sunday, April 19th, 2020

Inovio Pharmaceuticals Inc (INO) is near the top in its industry group according to InvestorsObserver. INO gets an overall rating of 72. That means it scores higher than 72 percent of stocks. Inovio Pharmaceuticals Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 6 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Inovio Pharmaceuticals Inc (INO) stock has risen 8.82% while the S&P 500 is lower by -0.22% as of 10:32 AM on Thursday, Apr 16. INO is up $0.63 from the previous closing price of $7.14 on volume of 5,210,923 shares. Over the past year the S&P 500 is down -4.25% while INO is up 108.87%. INO lost -$1.21 per share the over the last 12 months.

To screen for more stocks like INO click here.

See more here:
Is Inovio Pharmaceuticals Inc (INO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Investors should be cautious on the potential for Gilead’s drug Remdesivir, analysts say – CNBC

Sunday, April 19th, 2020

A new report from STAT News on Gilead's experimental drug Remdesivir serves as an encouraging update on the drug's potential to fight Covid-19, however analysts argue it's largely anecdotal and should be interpreted with caution.

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS, both caused by coronaviruses.

According to the report from an ongoing phase three trial at a University of Chicago hospital, patients showing severe Covid-19 symptoms who were given the drug saw rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than one week.

Gilead commented that, "the totality of the data need to be analysed in order to draw any conclusions from the trial," in a statement to Reuters. A statement from the University of Chicago Medicine said that "drawing any conclusions at this point is premature and scientifically unsound."

Jefferies equity analyst Michael J. Yee published in a research note that this Chicago report provides an "incremental positive" but he assumes this significant short-term move in Gilead's share price will probably pull back a bit given eventual broader awareness that this is not the actual phase three data and that this is overdone in the near term.

JPMorgan biotechnology equity analysts wrote in a published research note Thursday that "this clinical trial experience appears to represent another encouraging, albeit largely anecdotal, data point for this high-profile drug candidate."

Meanwhile, the Barclays health-care team called the update "encouraging" but note that questions persist.

The report from the Chicago hospital comes amid mounting anecdotal evidence supporting the drug's potential effectiveness in treating the virus. Last week, the New England Journal of Medicine published an analysis showing that two thirds of a small group of severely ill patients saw their condition improve after taking the drug. These patients were given Remdesivir as part of a compassionate use program which allows doctors to provide patients with unauthorized treatments when no other treatment is available.

There was no control group in the University of Chicago study. As CNBC's Meg Tirrell has highlighted, this is not controlled clinical trial data it is a glimpse into what one of the sites that is running the trial is seeing.

The information reported by STAT News came from an internal discussion among faculty members at a University of Chicago hospital captured on video, it was not official data released by Gilead or any other trial leader.

Furthermore, this data comes from a single trial site. The Barclays health-care equity research team wrote: "While these data are encouraging, they are uncontrolled and from a single center."

Jefferies echoes this point: "Similar to the NEJM publication last week, yesterday's reports are based on one site and there is no placebo."

There is also debate around the severity of the patients included in the study. This data is part of an ongoing phase three trial of patients with severe Covid-19 symptoms. However, the patients were not intubated to start the study. Barclays adds that there will be debate around the patient population and how they compare to past cohorts.

"There's still a great deal we don't know, and thus we hesitate to put too much into the results generated at a single center without a control group," said JPMorgan.

"Fortunately, we don't have to wait long for a Phase 3 readout in severe patients."

Gilead expects results from its trials with patients with severe Covid-19 later this month. Data from its trials on patients with moderate symptoms is expected in May.

In addition to these two trials being run by Gilead, there are several others underway concurrently to evaluate Remdesivir, including a phase two trial run by the National Institute of Health which is an adaptive, randomized, double-blind, placebo-controlled trial.

Barclays adds that data from Gilead's clinical trials on severe cases due at the end of this month could support approval or expanded use authorization. A treatment is not going to end the pandemic. But it will provide a critical bridge to the ultimate panacea a vaccine.

CNBC's Berkeley Lovelace contributed to this article.

Read more:
Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say - CNBC

Read More...

Free First-Person Adventure Game Allows Students to Learn Biotechnology Processes As They Hunt for the Virus during a Pandemic – GlobeNewswire

Sunday, April 12th, 2020

Orlando, Fla., April 07, 2020 (GLOBE NEWSWIRE) -- Mission Biotech, an educational, immersive 3D game featuring many hours of gameplay and challenges, is being offered free to educators as well as students interested in learning how scientists search and test for clues to identify a virus during a pandemic outbreak.

The game presents an immersive storyline that teaches middle-school students and above the laboratory protocols and the real-world concepts, procedures, and tools of the biotechnology field. This free download is being announced in response to the COVID-19 outbreak to support teachers and students as they adapt to new ways of learning during this challenging time.

Mission Biotech is a great way to encourage careers in biotechnology, said Randy Brown, Applied Research Associates, Inc. (ARA) vice president and division manager of Virtual Heroes, which developed the game. This game offers students a way to play, learn, and become a real hero of tomorrow.

In the game, users play as part of a virtual team trying to stop the spread of dangerous pathogens, and the clock is ticking. The player is a new member of the National Laboratory for Biotechnology and Bioinformatics. On this, their first mission, players need to learn laboratory protocol while also understanding the basic scientific concepts behind biotechnology processes.

Gameplay includes discovering and using high-tech, fully-functional laboratory equipment, and features more than 50 different inventory items and a wide range of clues to find and use. Players can collect up to 20 accomplishment badges and unlock mini-games; these games also reinforce the scientific concepts behind DNA extraction and Polymerase Chain Reaction (PCR) processes. These processes are being used in real life today to test for pathogens such as the novel coronavirus. Reference materials are also available for educators and learners on the download site.

With schools closing across the nation, we want to do our part to leverage any educational opportunities we can, Brown said. This software is an opportunity for students everywhere to engage in immersive biotech learning content while gaining a real-world understanding of the challenges facing scientists today.

Mission Biotech was funded by a grant from the National Science Foundation to the University of Florida, and developed on the Epic Games Unreal Engine by the Virtual Heroes Division of Applied Research Associates, Inc. This educational outreach is being coordinated between ARA, the Serious Play Conference, and the National Center for Simulation, all in Orlando, Florida.

Visit https://youtu.be/exMqEG-qOf8 for a game overview and then go to http://www.virtualheroes.biz/MissionBiotech to download Mission Biotech and start learning today.

Here is the original post:
Free First-Person Adventure Game Allows Students to Learn Biotechnology Processes As They Hunt for the Virus during a Pandemic - GlobeNewswire

Read More...

Nanoparticles in Biotechnology and Pharmaceuticals Market Challenges, Key Vendors, Drivers, Growth Opportunities and Forecast to 2026 – Germany…

Sunday, April 12th, 2020

The latest report published by Verified Market Research contains an in-depth analysis of the Nanoparticles in Biotechnology and Pharmaceuticals Market. The research report assesses the constantly changing market dynamics, which should affect the overall market development. Analysts have examined historical market success and compared it with current market trends to determine the course. For a detailed discussion of the Nanoparticles in Biotechnology and Pharmaceuticals market, analysts have segmented the market by application, product and end user. The research report was compiled using primary and secondary research methods to provide readers with an accurate and precise understanding of current developments in the Nanoparticles in Biotechnology and Pharmaceuticals market.

The Nanoparticles in Biotechnology and Pharmaceuticals Market Report includes the Competitive Landscape section, which provides a comprehensive and in-depth analysis of current market trends, evolving technologies and developments that benefit competitive businesses in the market. The report provides an overview of sales, demand and supply of data, futuristic costs and an analysis of growth over the forecast year.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=19246&utm_source=GEN&utm_medium=005

The Nanoparticles in Biotechnology and Pharmaceuticals Sales Market Report mainly contains the following Manufacturers:

Market size and limitation Nanoparticles in Biotechnology and Pharmaceuticals:

In recent years, the number of consumers has increased and innovative technologies in the industry are driving the broad growth of the market. The increasing preference of consumers affects the industry as an opportunity or a threat. Preferences and priorities act as idols as drivers of the growth of the market system. Industry experts always agree with the shortcomings. The biggest threat to the industry is changing technology every day

Why Buy This Report?

The report provides a comprehensive analysis of the Nanoparticles in Biotechnology and Pharmaceuticals market with detailed studies on various topics that will help players develop powerful growth strategies and consolidate a strong position in the industry. It offers a complete map of the behavior of market participants and the supplier landscape. Readers also receive information about key sustainability strategies that large companies use in the Nanoparticles in Biotechnology and Pharmaceuticals market. In addition, analysts have carefully evaluated the impact of these strategies on market growth and competition. Players could use the report to better prepare for future market challenges and strong competition in the Nanoparticles in Biotechnology and Pharmaceuticals market.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=19246&utm_source=GEN&utm_medium=005

Table of Content

1 Introduction of Nanoparticles in Biotechnology and Pharmaceuticals Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology 3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Nanoparticles in Biotechnology and Pharmaceuticals Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Deployment Model5.1 Overview

6 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Solution6.1 Overview

7 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Vertical7.1 Overview

8 Nanoparticles in Biotechnology and Pharmaceuticals Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Nanoparticles in Biotechnology and Pharmaceuticals Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Nanoparticles-in-Biotechnology-and-Pharmaceuticals-Market/?utm_source=GEN&utm_medium=005

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Nanoparticles in Biotechnology and Pharmaceuticals Market Size, Nanoparticles in Biotechnology and Pharmaceuticals Market Trends, Nanoparticles in Biotechnology and Pharmaceuticals Market Forecast, Nanoparticles in Biotechnology and Pharmaceuticals Market Growth, Nanoparticles in Biotechnology and Pharmaceuticals Market Analysis

Follow this link:
Nanoparticles in Biotechnology and Pharmaceuticals Market Challenges, Key Vendors, Drivers, Growth Opportunities and Forecast to 2026 - Germany...

Read More...

Biotechnology Separation Systems Market Growth Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Germany English News

Sunday, April 12th, 2020

New Jersey, United States:The new report has been added by Market Research Intellect to provide a detailed overview of the Biotechnology Separation Systems Market. The study will help to better understand the Biotechnology Separation Systems industry competitors, the sales channel, Biotechnology Separation Systems growth potential, potentially disruptive trends, Biotechnology Separation Systems industry product innovations and the value / volume of size market (regional / national level, Biotechnology Separation Systems- Industrial segments), market share of the best actors / products.

Information has been added to the report to provide a realistic view of the industry based on data from Biotechnology Separation Systems manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Biotechnology Separation Systems branch. Market participants can use the report to take a look at the future of the Biotechnology Separation Systems market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=207653&utm_source=GEN&utm_medium=888

The report examines the competitive environment scenario observed with key players in Biotechnology Separation Systems sales, the profile of their business, their earnings, their sales, their business tactics, and the forecasting situations of the Biotechnology Separation Systems sales industry. According to studies, the Biotechnology Separation Systems sales market is very competitive and diverse due to global and local suppliers.

The Biotechnology Separation Systems Sales Market Report mainly contains the following Manufacturers:

Market Competition

The competitive landscape of the Biotechnology Separation Systems market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Biotechnology Separation Systems market, highlighting their key commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Report Highlights

Assessment of sales channels

innovation trends

sustainability strategies

Niche market trends

Market entry analysis

market size and forecast

The geographic department provides data that give you an overview of the turnover of companies and sales figures for the growth activity Biotechnology Separation Systems for electrical meters. Here are the strengths of the geographic divisions: North America (United States, Canada and Mexico), Europe (Germany, Spain, France, Great Britain, Russia and Italy and more), Asia-Pacific (China, Japan, Korea, India and Southeast Asia) and more ), South America (Brazil, Argentina, Colombia), the Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa) and ROW.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=207653&utm_source=GEN&utm_medium=888

Table of Content

1 Introduction of Biotechnology Separation Systems Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Biotechnology Separation Systems Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Biotechnology Separation Systems Market, By Deployment Model5.1 Overview

6 Biotechnology Separation Systems Market, By Solution6.1 Overview

7 Biotechnology Separation Systems Market, By Vertical7.1 Overview

8 Biotechnology Separation Systems Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Biotechnology Separation Systems Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/%ef%bb%bfbiotechnology-separation-systems-market-size-and-forecast/?utm_source=GEN&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Biotechnology Separation Systems Market Size, Biotechnology Separation Systems Market Growth, Biotechnology Separation Systems Market Forecast, Biotechnology Separation Systems Market Analysis, Biotechnology Separation Systems Market Trends, Biotechnology Separation Systems Market

See the rest here:
Biotechnology Separation Systems Market Growth Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Germany English News

Read More...

What Is GeneReach Biotechnologys (GTSM:4171) P/E Ratio After Its Share Price Rocketed? – Simply Wall St

Sunday, April 12th, 2020

Its great to see GeneReach Biotechnology (GTSM:4171) shareholders have their patience rewarded with a 56% share price pop in the last month. Zooming out, the annual gain of 150% knocks our socks off.

Assuming no other changes, a sharply higher share price makes a stock less attractive to potential buyers. In the long term, share prices tend to follow earnings per share, but in the short term prices bounce around in response to short term factors (which are not always obvious). The implication here is that deep value investors might steer clear when expectations of a company are too high. One way to gauge market expectations of a stock is to look at its Price to Earnings Ratio (PE Ratio). Investors have optimistic expectations of companies with higher P/E ratios, compared to companies with lower P/E ratios.

See our latest analysis for GeneReach Biotechnology

We can tell from its P/E ratio of 49.49 that there is some investor optimism about GeneReach Biotechnology. As you can see below, GeneReach Biotechnology has a higher P/E than the average company (19.0) in the medical equipment industry.

GeneReach Biotechnologys P/E tells us that market participants think the company will perform better than its industry peers, going forward. The market is optimistic about the future, but that doesnt guarantee future growth. So further research is always essential. I often monitor director buying and selling.

Probably the most important factor in determining what P/E a company trades on is the earnings growth. If earnings are growing quickly, then the E in the equation will increase faster than it would otherwise. And in that case, the P/E ratio itself will drop rather quickly. A lower P/E should indicate the stock is cheap relative to others and that may attract buyers.

In the last year, GeneReach Biotechnology grew EPS like Taylor Swift grew her fan base back in 2010; the 141% gain was both fast and well deserved.

Dont forget that the P/E ratio considers market capitalization. That means it doesnt take debt or cash into account. Theoretically, a business can improve its earnings (and produce a lower P/E in the future) by investing in growth. That means taking on debt (or spending its cash).

Such spending might be good or bad, overall, but the key point here is that you need to look at debt to understand the P/E ratio in context.

Since GeneReach Biotechnology holds net cash of NT$177m, it can spend on growth, justifying a higher P/E ratio than otherwise.

GeneReach Biotechnologys P/E is 49.5 which is way above average (14.9) in its market. Its net cash position is the cherry on top of its superb EPS growth. So based on this analysis wed expect GeneReach Biotechnology to have a high P/E ratio. What is very clear is that the market has become significantly more optimistic about GeneReach Biotechnology over the last month, with the P/E ratio rising from 31.7 back then to 49.5 today. If you like to buy stocks that have recently impressed the market, then this one might be a candidate; but if you prefer to invest when there is blood in the streets, then you may feel the opportunity has passed.

When the market is wrong about a stock, it gives savvy investors an opportunity. If the reality for a company is better than it expects, you can make money by buying and holding for the long term. So this free report on the analyst consensus forecasts could help you make a master move on this stock.

Of course you might be able to find a better stock than GeneReach Biotechnology. So you may wish to see this free collection of other companies that have grown earnings strongly.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
What Is GeneReach Biotechnologys (GTSM:4171) P/E Ratio After Its Share Price Rocketed? - Simply Wall St

Read More...

Biotech Firms May Be Key To Beating The Coronavirus, But They’re Not Immune To Financial Worry – WBUR

Sunday, April 12th, 2020

Scott Robinson used to be an investment banker, so he has a pretty good idea why it's tough these days to raise money for his Cambridge biotechnology startup, MicroQuin even though the company believes its approach to fighting cancer could show promise against the coronavirus.

"At the moment, a lot of the funding has really been allocated to things that people are thinking are quick wins stuff like drug repurposing or vaccinations," he said.

For a handful of drugmakers taking on the coronavirus, fundraising is no problem right now. But for many other Massachusetts biotechs, the pandemic threatens to stop the flow of money.

If you're a company like MicroQuin, and you don't have a coronavirus vaccine candidate or a drug ready to test against COVID-19 good luck getting new financing.

And there's no telling when investors will feel comfortable spending again.

"We've seen many investors sort of push the pause button for the next quarter, as they assess the market," saidJonathan Norris, a managing director at Silicon Valley Bank. He spoke this week on a virtual panel organized by LabCentral, the Kendall Square workspace where Robinson's company and about 70 others are based.

"We just don't know how long this pandemic is going to last," Norris said. "The big financial questions that investors are talking about are, 'What's going to happen in the public markets? Will IPOs happen?'"

Initial public offerings of stock can be critical to biotechs. They often infuse cash into young firms that have raised venture capital but don't yet have any FDA-approved drugs to produce revenue.

The Nasdaq Biotechnology Index has recovered some losses, after falling more than 20% last month. But it's still a scary time, said Robert Urban, the former head of Johnson & Johnson's innovation division. J&J has secured a $1 billiondeal including federal grants to try to develop a vaccine, but most companies aren't in that position.

"We have some tough days ahead and maybe tough months ahead," Urban said of the biotech industry. "So, anyone who's running a business a life science business, in some ways, may be even more difficult because they require so much money needs to be taking some very careful care of the decisions that they make."

Urban and Norris were joined on the LabCentral panel by Matt McTygue, an attorney who represents venture capitalists. It's not that investors aren't doing any deals, McTygue said, but he offered a warning: "Financings that do happen during this time are going to be on more investor-favorable terms, more dilutive terms."

In other words, entrepreneurs who are desperate for funding may have to give up bigger-than-usual ownership stakes in their companies.

Read the rest here:
Biotech Firms May Be Key To Beating The Coronavirus, But They're Not Immune To Financial Worry - WBUR

Read More...

Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement – Agri-Pulse

Sunday, April 12th, 2020

The COVID-19 outbreak is gripping our planet like no other health crisis in recent history. Overt collaboration and policy action are required to meet this challenge and, as importantly, prepare for the future. Elevating and prioritizing the interconnectedness of living things through One Health strategies and modernizing Americas animal biotechnology regulatory approach are two policies Congress and the White House must confront. In fact, they are long overdue.

Sixty percent of human diseases begin in animals.Scientists are confident that the COVID outbreak originated in batsand then was spread through another animal and then to humans, like the 2002-03 SARS outbreak. As the climate changes and populations grow and move, these zoonotic diseases will become more prevalent and potentially more dangerous.

Aside from the dreadful health implications, the resulting economic costs of a pandemic are profound.The World Bank estimates that, between 1997 and 2009, the global costs from six zoonotic outbreaks exceeded $80 billion. While we wont know the total impact for some time, COVID-19 has already producedone of the sharpest economic downturns in U.S. history and is costing the U.S. treasury alone trillions of dollars.

Society was woefully unprepared for this pandemic. We must employ modern approaches to be ready for future outbreaks. One Health collaboration eliminates barriers that often exist between human health, animal health, and environmental health strategies to create smarter, multi-faceted and coordinated efforts.

BIO supports legislation such as the Advancing Emergency Preparedness Through One Health Act of 2019. This bill would direct the U.S. Department of Health and Human Services and the U.S. Department of Agriculture (USDA) to coordinate with other agencies and state and local leaders to advance a national One Health framework to better prevent, prepare for, and respond to zoonotic disease outbreaks like COVID-19. Congress and the White House must factor One Health into their efforts to address future pandemics.

Animal health and wellness is a critical component of One Health strategy. To help the U.S. better prepare for the future, we need changes to the U.S. animal biotechnologyregulatory system.The U.S. governments current approach to regulating animal biotechnology as a new animal drug has all but destroyed investment and blocked market access for a host of beneficial products.

Biotechnology, for example, could armpigs with resistanceto African Swine Fever. Similarly,scientists have developed achickenthat is resistant to contracting and transmitting avian influenza.

Other innovations in animal biotechnology may be able prevent, prepare for, and respond to outbreaks of infectious diseases such as coronavirus, Ebola, MERS, Zika, among others, by providing prevention strategies andtreatments for humans.

Unfortunately, the United States regulatory system for animal biotechnology is not appropriately science- or risk-based, and as a result we are falling behind other countries, such as Brazil, where innovative start-ups are finding more support.

Indeed, despite decades of animal biotechnology research and advances, only one biotech food animal has been approved to date the AquaBounty salmon which languished in the U.S. regulatory system for more than two decades and still has not hit the market because ofpolitical interference.

The current crisis underscores the urgent need to break down roadblocks to progress.

BIO is calling on the White House to direct the U.S. Food and Drug Administration (FDA) and the USDA to clarify within 30 days a plan to overhaul the current regulatory approval process for animal biotechnology.

In alettersent to the President, BIO implores the need for a new approach that 1) more appropriately draws upon existing legal authorities to safeguard animal health, food safety, and the environment; 2) incentivizes research and investment in the technology; and 3) ensures safe and affordable products reach consumers as soon as possible.

A joint agreement between both agencies will help farmers, innovators, and consumers realize the benefits that modern technology can bring to the United States and the world. And just may well prevent the next potential animal to human disease outbreak.

Dana OBrien,Executive Vice President,Food & AgricultureBiotechnology Innovation Organization (BIO)

The rest is here:
Opinion: Coronavirus outbreak stresses need for One Health and animal biotech advancement - Agri-Pulse

Read More...

Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic – Yahoo Finance

Sunday, April 12th, 2020

MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the companys response, operationally and scientifically.

Dear Generex Shareholders,

The emergence and rapid escalation of the COVID-19 pandemic has deeply impacted our lives as we never could have imagined. During these uncertain times the health and well-being of our Generex family, including our employees, shareholders, investors and partners is paramount. For the well-being of all of our stakeholders, we are committed to following the precautions of health advisors and adhering to suggestions, advice, and laws set up by local municipalities, cities, states, and the federal government to stop this pandemic that has disrupted the world. Generex Biotechnology remains dedicated to safeguarding your investment in GNBT as we continue working towards positive outcomes into the future through our strategic initiatives and development programs, including our previously announced efforts to develop a vaccine for the SARS-CoV-2 virus.

We want to take this time to update shareholders on the steps we are taking to efficiently manage the businesses of Generex and our subsidiaries through these challenging times. We are virtually fully operational with all our business management teams and their employees through video conference and are committed to following through with our short, mid and long-term goals and plans to add value for our shareholders.

As reported Generex has jumped into the vaccine race with its Ii-Key-COVID-19 Complete Vaccine, which is designed to activate both the cellular (CD4 and CD8 T cells) and humoral (antibody) immune responses. As previously reported, we have signed an agreement with a Chinese consortium to develop our Complete Vaccine for China. Since signing the agreement, Generex has developed and refined our vaccine plans and has invoiced the Chinese consortium for the upfront payment and licensing fee.

Generex has also partnered with EpiVax, a leader in computational vaccinology, that has developed algorithms to identify specific amino acid peptide sequences or epitopes that are predicted to activate the various cellular components of the immune system including CD4 T Cells, CD8 T Cells, and B Cells that produce antibodies. An additional advantage of their vaccinology algorithms is their ability to dehumanize peptide sequences to minimize autoimmune reactions. EpiVax has identified a series of epitopes of the SARS-CoV-2 viral proteins that may be used to produce a vaccine. Generex plans to manufacture laboratory scale amounts of the EpiVax peptides linked with our Ii-Key technology to screen against blood samples from patients who have recovered from COVID-19. We are in the process of identifying hospitals and research centers that can provide us with the blood samples for peptide epitope screening. We expect this screening process to yield the best 3 to 5 Ii-Key peptides that we anticipate will make the most safe and effective vaccine for human clinical trials.

To advance our vaccine development efforts, the team at Generex has been proactive in reaching out to a number of countries, and we have had productive conversations with several government officials, Ministries of Health, and other key influencers to describe our technology, our clinical strategy, potential manufacturing partners, and our rapid path to vaccination for their populations. Generex has also met and had discussions with U.S. government agencies to provide them with details of our Ii-Key peptide vaccine technology, and we are in discussions with the decision makers for federal funding and partnership. It has been a slow process, but we believe that vaccines are now getting more government attention as local, state, and federal officials recognize the severity of this pandemic and the likelihood that the virus will return next year.

Generex has identified a clinical research organization, regulatory consultants, and clinical research sites to conduct our trials, and we are working with our contract manufacturing partners for AE37 to produce our Ii-Key-SARS-CoV-2 peptide vaccine for human clinical trials and population vaccination initiatives. We are also in discussions with pharmaceutical companies to include their vaccine adjuvants as part of the clinical trial design to evaluate the potential of using adjuvant in our vaccine formulation.

Story continues

Generex is highly confident in our rapid vaccine development program and in our plans to scale the manufacturing of Ii-Key- SARS-CoV-2 peptide vaccines to conduct not only the clinical trials required to meet the approval standards of global regulatory authorities, but to meet government expectations for mass population vaccination.

In conclusion, while the COVID-19 pandemic is surely a fast evolving situation with multiple layers of complexity, we believe market conditions should ultimately favor long-term minded, value oriented, and fundamental investors. Generex has many subsidiaries and many assets, from its FDA-cleared wound care product Excellegen, to our development products in inflammatory bowel diseases, diabetes, infectious disease, and cancer, to our pending operations in Arizona, with the ultimate vision of building a HMO with, in our opinion, unprecedented benefit packages through our own products, devices, and ancillary services. Based on all these efforts and assets, it is my belief that Generex has the staying power to thrive and bring value to our shareholders. Rest assured, Generex is well equipped to navigate the current environment as we remain focused on our core competencies and businesses while positioning our high-value assets for the future.

In the immediate days ahead, we will continue working to solidify the development path and government partnerships to complete our Ii-Key-SARS-CoV-2 Complete Vaccine program so that we can make a difference not only for Generex, our employees, and our shareholders, but for the world. Finally, we thank you all for your continued support as we navigate through this difficult period together, and please everyone, stay safe, be well and take care of your families and friends.

Sincerely,Joe MoscatoCEO

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 1-800-391-6755 Extension 222 investor@generex.com

See the original post:
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic - Yahoo Finance

Read More...

Anti-Covid consortium in India working on therapeutic antibodies – India New England

Sunday, April 12th, 2020

New DelhiAn anti-Covid consortium of experts with the assistance of Department of Biotechnology is working towards producing therapeutic antibodies against Covid-19.

In India, one such effort is being led by Vijay Chaudhary at the University of Delhi South Campus-Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), with the support of the Department of Biotechnology in the Ministry of Science and Technology.

Chaudharys group is isolating genes encoding antibodies, which can neutralise the SARS-CoV-2, using a large antibody library already available in-house as well as a library made from cells of patients who have recovered from COVID-19 infection.

These antibody genes will be used to produce recombinant antibodies in the laboratory, which, if successful in neutralising the virus, will become a perennial source of antibodies against this virus, both for prophylactic and therapeutic purposes.

This work is being undertaken as part of an Anti-Covid consortium under the leadership of Chaudhary and involving Amulya Panda at National Institute of Immunology and Sanjay Singh at Gennova Biopharmaceutical Limited, Pune (GBL).

Covid 19 is caused by the novel SARS coronavirus-2 (SARS-CoV-2) and it is resulting in many deaths. However, a large number of infected people are also recovering despite not having any specific treatment. This is because of antibodies produced within the body in response to the virus invasion.

Over the years, passive transfer of antibodies obtained from the plasma of convalescent patients cured of infection has been used for treatment of numerous disease conditions such as diphtheria, tetanus, rabies and ebola.

Today such therapeutic antibodies can be produced in the laboratory by DNA-based recombinant technologies. Efforts are in full swing globally to produce therapeutic antibodies against SARS-CoV-2, a statement by Department of Biotechnology said. (IANS)

See original here:
Anti-Covid consortium in India working on therapeutic antibodies - India New England

Read More...

(2020-2025) Agriculture Biotechnology Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers…

Sunday, April 12th, 2020

Latest Report onAgriculture Biotechnology Market

The report titled Global Agriculture Biotechnology Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Agriculture Biotechnology market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Agriculture Biotechnology market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Agriculture Biotechnology market is carefully analyzed and researched about by the market analysts.

Agriculture Biotechnology Market competition by top manufacturers/ Key player Profiled: ADAMA Agricultural Solutions, Vilmorin, Bayer, Biocentury Transgene, Certis, Dow AgroSciences

Request a sample copy of the report with Detail TOC and List of Figures @ https://www.alexareports.com/report-sample/692707

Global Agriculture Biotechnology Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2024. According to the latest report added to the online repository of Alexareports the Agriculture Biotechnology market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2024.

Agriculture Biotechnology Market Segment by Type covers: Biochips, Deoxy ribonucleic acid (DNS) sequencing, Genome editing tools, Ribonucleic acid interference (RNAI), Synthetic biology

Agriculture Biotechnology Market Segment by Application covers:Transgenic crops market, Synthetic biology-enabled products market

After reading the Agriculture Biotechnology market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Agriculture Biotechnology market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalAgriculture Biotechnology market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Agriculture Biotechnology market?What are the key factors driving the global Agriculture Biotechnology market size?Who are the key manufacturers in Agriculture Biotechnology market space?What are the market opportunities, market risk and market overview of the Agriculture Biotechnology market?What are sales, revenue, and price analysis of top manufacturers of Agriculture Biotechnology market?Who are the distributors, traders, and dealers of Agriculture Biotechnology market?What are the Agriculture Biotechnology market opportunities and threats faced by the vendors in the global Agriculture Biotechnology industries?What are sales, revenue, and price analysis by types and applications of Agriculture Biotechnology market?What are sales, revenue, and price analysis by regions of Agriculture Biotechnology industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/692707

Some of the Major Highlights of TOC covers:

Agriculture Biotechnology Regional Market Analysis

Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Production by RegionsGlobal Agriculture Biotechnology Revenue by RegionsAgriculture Biotechnology Consumption by RegionsAgriculture Biotechnology Segment Market Analysis (by Type)

Global Agriculture Biotechnology Production by TypeGlobal Agriculture Biotechnology Revenue by TypeAgriculture Biotechnology Price by TypeAgriculture Biotechnology Segment Market Analysis (by Application)

Global Agriculture Biotechnology Consumption by ApplicationGlobal Agriculture Biotechnology Consumption Market Share by Application (2014-2020)Agriculture Biotechnology Major Manufacturers Analysis

Agriculture Biotechnology Production Sites and Area ServedProduct Introduction, Application and SpecificationAgriculture Biotechnology Production, Revenue, Ex-factory Price and Gross Margin (2014-2020)Main Business and Markets Served

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/692707

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

See the rest here:
(2020-2025) Agriculture Biotechnology Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers...

Read More...

Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? – Yahoo Finance

Sunday, April 12th, 2020

Puma Biotechnology, Inc.'s (NASDAQ:PBYI): Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. The US$283m market-cap company announced a latest loss of -US$75.6m on 31 December 2019 for its most recent financial year result. As path to profitability is the topic on PBYIs investors mind, Ive decided to gauge market sentiment. In this article, I will touch on the expectations for PBYIs growth and when analysts expect the company to become profitable.

Check out our latest analysis for Puma Biotechnology

PBYI is bordering on breakeven, according to the 8 Biotechs analysts. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$11m in 2022. So, PBYI is predicted to breakeven approximately 2 years from now. What rate will PBYI have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 62%, which is extremely buoyant. If this rate turns out to be too aggressive, PBYI may become profitable much later than analysts predict.

NasdaqGS:PBYI Past and Future Earnings April 8th 2020

Underlying developments driving PBYIs growth isnt the focus of this broad overview, however, bear in mind that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing I would like to bring into light with PBYI is its debt-to-equity ratio of over 2x. Typically, debt shouldnt exceed 40% of your equity, which in PBYIs case, it has significantly overshot. Note that a higher debt obligation increases the risk in investing in the loss-making company.

There are too many aspects of PBYI to cover in one brief article, but the key fundamentals for the company can all be found in one place PBYIs company page on Simply Wall St. Ive also put together a list of key aspects you should further research:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Follow this link:
Puma Biotechnology, Inc. (NASDAQ:PBYI): When Will It Breakeven? - Yahoo Finance

Read More...

This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low – The InvestChronicle

Sunday, April 12th, 2020

For the readers interested in the stock health of Vir Biotechnology, Inc. (VIR). It is currently valued at $33.19. When the transactions were called off in the previous session, Stock hit the highs of $38.74, after setting-off with the price of $36.5. Companys stock value dipped to $32.15 during the trading on the day. When the trading was stopped its value was $29.00.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Vir Biotechnology, Inc. shares are logging -55.74% during the 52-week period from high price, and 184.91% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $11.65 and $75.00.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Vir Biotechnology, Inc. (VIR) recorded performance in the market was 130.62%, having the revenues showcasing 140.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.21B, as it employees total of 229 workers.

During the last month, 3 analysts gave the Vir Biotechnology, Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 22.19, with a change in the price was noted +19.48. In a similar fashion, Vir Biotechnology, Inc. posted a movement of +146.80% for the period of last 100 days, recording 572,027 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for VIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of Vir Biotechnology, Inc. in the period of last 50 days is set at 28.28%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 20.94%. In the last 20 days, the companys Stochastic %K was 11.97% and its Stochastic %D was recorded 11.37%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 130.62%. The shares increased approximately by 1.54% in the 7-day charts and went up by -15.45% in the period of the last 30 days. Common stock shares were driven by 140.86% during last recorded quarter.

Here is the original post:
This is to seal it as Vir Biotechnology, Inc. (VIR) shares are up 184.91% from its 52-week low - The InvestChronicle

Read More...

Page 30«..1020..29303132..4050..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick